Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02, Zacks reports.
Alpha Tau Medical Trading Up 11.1%
Shares of DRTS stock opened at $3.10 on Tuesday. The company’s fifty day moving average price is $2.64 and its 200-day moving average price is $2.90. The stock has a market cap of $218.18 million, a PE ratio of -7.21 and a beta of 0.92. Alpha Tau Medical has a 12 month low of $1.75 and a 12 month high of $4.39.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research report on Tuesday, April 29th.
About Alpha Tau Medical
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
See Also
- Five stocks we like better than Alpha Tau Medical
- Investing In Automotive Stocks
- Here’s The Bull Case For Roku Stock With Double-Digit Upside
- What is the MACD Indicator and How to Use it in Your Trading
- Spotify Stock’s Rally Still Has Legs To Run Higher
- Top Stocks Investing in 5G Technology
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
